X-Chem is an industry-leading provider of DNA-Encoded Library (DEL)-based discovery services. Leveraging a proprietary DEL platform with libraries containing over 200 billion small molecules, X-Chem provides drug discovery services to biopharma partners. X-Chem has licensed over seventy research programs, comprising hundreds of novel chemical entities, to companies throughout the US, Europe and Japan. DEL technology, allowing customers to screen billions of compounds simultaneously against a single biological target, is an innovative and high growth segment of the market as pharmaceutical companies look for access to cutting edge scientific expertise to support an increasingly challenging drug discovery process.
The Carlyle Group; Hellman & Friedman
BlackArch was retained by X-Chem to serve as its exclusive financial advisor.
BlackArch's Customized Solution
The transaction continues BlackArch’s strong presence in the pharmaceutical outsourcing and healthcare sectors and is representative of the firm’s focus on providing dedicated M&A advisory services to market-leading businesses.
GHO Capital has acquired X-Chem. X-Chem will benefit from GHO’s expertise, global network and international resources to accelerate growth. With continued investment and support from GHO, X-Chem will leverage its best-in-class technology to expand its capabilities and grow internationally.